NCT04648202: FS120 First in Human Study in Patients With Advanced Malignancies

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have progressed on up to 2 prior regimens for metastatic disease
Exclusions: Patients with prior therapy of any OX40 agonist, CD137 (4-1BB) agonist, CD40 agonist, GITR, or CD27 targeting therapy (single agent or combination); Patients with prior therapy of more than 1 line of treatment with immune-checkpoint inhibitors; Patients with unstable, symptomatic, uncontrolled brain metastases- see trial for details

Comments are closed.

Up ↑